Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2024
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Two-Thirds of People with Atopic Dermatitis of Color Saw Improvement in Lebrikizumab Study
Details : Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
October 03, 2024
Details:
Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor approved for patients 12 years or older with moderate-to-severe Atopic Dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2024
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Lilly's EBGLYSS™ for Moderate-to-Severe Atopic Dermatitis
Details : Ebglyss (lebrikizumab) is an approved high-affinity and potent IL-13 inhibitor approved for patients 12 years or older with moderate-to-severe Atopic Dermatitis.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
September 13, 2024
Details:
Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: Ebglyss
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe ...
Details : Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
November 17, 2023
Details:
Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: Ebglyss
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
September 15, 2023
Details:
Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, and FDA has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema).
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, and FDA has issued a complete response letter for the lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis (eczema).
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
February 10, 2023
Details:
LY3650150 (lebrikizumab) is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LY3650150 (lebrikizumab) is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
January 05, 2023
Details:
Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the IL-13 protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.
Lead Product(s): Lebrikizumab,Undisclosed
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2022
Lead Product(s) : Lebrikizumab,Undisclosed
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the IL-13 protein with high affinity to specifically prevent the formation of IL-13Rα1/IL-4Rα (Type 2 receptor) which blocks downstream signaling through the IL-13 pathway.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
November 04, 2022
Details:
New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2022
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New, late-breaking data show lebrikizumab responders reported long-lasting results at one year of treatment across measures of improvement in skin clearance, itch and disease extent and severity.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
August 09, 2022
Details:
Lebrikizumab (LY3650150), is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2022
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lebrikizumab (LY3650150), is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
June 06, 2022
Details:
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab, an investigational IL-13 inhibitor monotherapy.
Lead Product(s): Lebrikizumab
Therapeutic Area: Dermatology Brand Name: LY3650150
Study Phase: Phase IIIProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2022
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab, an investigational IL-13 inhibitor monotherapy.
Product Name : LY3650150
Product Type : Antibody
Upfront Cash : Inapplicable
March 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD :
TE Code :
Brand Name : PRAXBIND
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.5G/50ML
Approval Date :
Application Number : 761025
RX/OTC/DISCN :
RLD :
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Norway
Brand Name : Ebglyss
Dosage Form : Solution for injection in a pre-filled pen
Dosage Strength : 250 mg
Packaging : Pre-filled pen 2 2ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Ebglyss
Dosage Form : Solution for injection, solution in pre-filled syringe
Dosage Strength : 250 mg
Packaging : Pre-filled syringe 2 2ml
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
ABOUT THIS PAGE
